Kepreptol Warnings

Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including this drug, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.
Psychiatric Reactions: Partial onset seizure: Adults: In adults experiencing partial onset seizures, levetiracetam use is associated with the occurrence of central nervous system adverse events that can be classified into the following categories 1) Somnolence and fatigue, 2) coordination difficulties, and 3) behavioral abnormalities. Somnolence, asthenia and coordination difficulties occurred most frequently within the first 4 weeks of treatment.
Pediatric Patients: In pediatric patients experiencing partial onset seizures, Levetiracetam is associated with somnolence, fatigue, and behavioral abnormalities.
Primary generalized tonic-clonic seizures: This drug is associated with behavioral disorders in patients 6 years of age and older with primary generalized tonic-clonic seizures.
Discontinuation: To minimize increasing the seizure onset frequency, if Antiepileptic drugs (AEDs), including this drug, has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg:500 mg decreases twice daily every two to four weeks; in children, dose decrease should not exceed 10 mg/kg twice daily every two weeks).